New Agents

92-C-0137: A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Intrathecal Methotrexate Overdoses

Principal Investigator: Dr. Brigitte Widemann

01-C-0091: A Phase I Trial and Pharmacokinetic Study of Tariquidar, a P-Glycoprotein Inhibitor, in Combination with Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients with Refractory Solid Tumors Including Brain Tumors

Principal Investigator: Dr. Frank Balis

02-C-0031: A Phase I trial and pharmacokinetic study of BMS-247550 (NSC 710428), an epothilone B analog, in pediatric patients with refractory solid tumors

Principal Investigator: Dr. Brigitte Widemann

02-C-0141: A Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Pediatric Patients with Refractory Solid Tumors

Principal Investigator: Dr. Frank Balis

Last Updated: :July 25, 2006

NCI Home Page|| NIH Home Page

© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute